文献速递胸部肿瘤

基于BRCA1与RAP80 mRNA表达定制化疗在中国晚期非小细胞肺癌患者中的多中心随机试验

[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2016-01-01

该多中心随机试验将124例晚期NSCLC患者按1∶3随机分入对照组或实验组,对照组接受多西他赛/顺铂,实验组根据BRCA1与RAP80 mRNA表达水平分配至吉西他滨/顺铂、多西他赛/顺铂或多西他赛单药方案。结果显示实验组各亚组与对照组在客观缓解率、无进展生存期和总生存期上均无统计学显著差异。

要点

  • 实验组各亚组与对照组相比,ORR、PFS和OS均无统计学显著差异。
  • RAP80 mRNA低表达患者对吉西他滨/顺铂化疗有生存获益更好和缓解率更高的趋势。
  • 常见不良事件包括中性粒细胞减少、恶心、贫血和乏力。

核心结论

  • 实验组各亚组与对照组相比,客观缓解率、无进展生存期和总生存期均未观察到统计学显著差异。
  • RAP80 mRNA低表达患者对吉西他滨/顺铂化疗有生存更好和缓解率更高的趋势。

研究设计与样本

  • 多中心随机试验,筛选226例晚期NSCLC患者,最终124例随机分入对照组或实验组(1∶3)。
  • 对照组接受多西他赛/顺铂;实验组按RAP80和BRCA1 mRNA表达水平分配至吉西他滨/顺铂(Arm 1)、多西他赛/顺铂(Arm 2)或多西他赛单药(Arm 3)。
  • 主要终点为无进展生存期(PFS)。

主要发现

  • 四个亚组(对照组、Arm 1、Arm 2、Arm 3)的ORR分别为22.6%、48.4%、30.3%和19.2%(P=0.08)。
  • 四个亚组的PFS分别为4.74、5.59、3.78和2.73个月(P=0.55)。
  • 四个亚组的OS分别为10.82、14.44、10.86和10.86个月(P=0.84)。
  • 常见不良事件包括中性粒细胞减少、恶心、贫血和乏力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: BRCA1 (breast cancer susceptibility gene 1) and RAP80 (receptor-associated protein 80) play key roles in predicting chemosensitivity of platinum and taxanes. A randomized trial was carried out to compare non-selected cisplatin-based chemotherapy with therapy customized according to BRCA1 and RAP80 expression. Methods: Advanced stage NSCLC patients whose tumor specimen was sufficient for molecular analysis were randomized (1∶3) to the control or experimental arm. Patients in the control arm received docetaxel/cisplatin; in the experimental arm, patients with low RAP80 expression received gemcitabine/cisplatin (Arm 1), those with intermediate/high RAP80 expression and low/intermediate BRCA1expression received docetaxel/cisplatin (Arm 2), and those with intermediate/high RAP80 expression and high BRCA1 expression received docetaxel alone (Arm 3). The primary end point was progression-free survival (PFS). Results: 226 patients were screened and 124 were randomized in this trial. ORR in the four subgroups was 22.6%, 48.4%, 30.3% and 19.2%, respectively (P=0.08); PFS was 4.74, 5.59, 3.78 and 2.73 months, respectively (P=0.55); and OS was 10.82, 14.44, 10.86 and 10.86 months, respectively (P=0.84). The common adverse effects included neutropenia, nausea, anemia and fatigue. Conclusions: No statistically significant difference of ORR, PFS or OS is observed in the experimental arms compared with the control arm. Patients with low RAP80 mRNA levels have a trend of better survival and higher response rate to gemcitabine/cisplatin chemotherapy.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wei J, Qian XP, Zou ZY, et al. [Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998448. doi:10.3760/cma.j.issn.0253-3766.2016.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。